No. of Recommendations: 3
I feel like PFE is less of a R&D pharma at this point than a LBO shop pretending to be one, similarly to how Broadcom/AVGO pretends to be a technology company. Their "competency" is harvesting cash flow from acquisitions towards future acquisitions. Unlike AVGO, they have a ticking patent clock before Mylan / Teva / Reddy et al are nipping at their heels. They fill a niche in the economic ecosystem, but I'd rather do basket plays on development stage companies (things like
X (Twitter): Adam Feuerstein ✡️ (@adamfeuerstein) / X discusses much better than myself).. and I avoid those, too. The Buffett "too hard pile" principle.
